Literature DB >> 19521971

Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients.

Ana M Ferreira1, Helga Westers, Sónia Sousa, Ying Wu, Renée C Niessen, Maran Olderode-Berends, Tineke van der Sluis, Peter T W Reuvekamp, Raquel Seruca, Jan H Kleibeuker, Harry Hollema, Rolf H Sijmons, Robert M W Hofstra.   

Abstract

A progressive accumulation of genetic alterations underlies the adenoma-carcinoma sequence of colorectal cancer. This accumulation of mutations is driven by genetic instability, of which there are different types. Microsatellite instability (MSI) is the predominant type present in the tumours of Lynch syndrome patients and in a subset of sporadic tumours. It is generally accepted that MSI can be found in the early stages of tumour progression, such as adenomas; however, the frequencies reported vary widely among studies. Moreover, data on the qualitative differences between adenomas and carcinomas, or between tumours of hereditary and sporadic origin, are scarce. We compared MSI in samples of colorectal adenoma and colorectal carcinoma in order to identify possible differences along the adenoma-carcinoma sequence. We compared germline mismatch repair (MMR) gene mutation carriers and non-carriers, to address possible differences of instability patterns between Lynch syndrome patients and patients with sporadic tumours. We found a comparable relative frequency of mono- and dinucleotide instability in sporadic colorectal adenomas and carcinomas, dinucleotide instability being observed most frequently in these sporadic tumours. In MMR gene truncating mutation carriers, the profile was different: colorectal adenomas showed predominantly mononucleotide instability and in colorectal carcinomas, also more mononucleotide than dinucleotide instability was detected. We conclude that MSI profiles differ between sporadic and Lynch syndrome tumours, and that mononucleotide marker instability precedes dinucleotide marker instability during colorectal tumour development in Lynch syndrome patients. As mononucleotide MSI proves to be highly sensitive for detecting mutation carriers, we propose the use of mononucleotide markers for the identification of possible Lynch syndrome patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521971     DOI: 10.1002/path.2573

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps.

Authors:  Matthew B Yurgelun; Ajay Goel; Jason L Hornick; Ananda Sen; Danielle Kim Turgeon; Mack T Ruffin; Norman E Marcon; John A Baron; Robert S Bresalier; Sapna Syngal; Dean E Brenner; C Richard Boland; Elena M Stoffel
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-18

3.  MSI detection and its pitfalls in CMMRD syndrome in a family with a bi-allelic MLH1 mutation.

Authors:  Aurélia Nguyen; Gaelle Bougeard; Meriam Koob; Marie Pierre Chenard; Anne Schneider; Christine Maugard; Natacha Entz-Werle
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

4.  Clinical relevance of microsatellite instability in colorectal cancer.

Authors:  Albert de la Chapelle; Heather Hampel
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Sally-Ann Pearson; Mark Clendenning; Mark A Jenkins; Aung Ko Win; Rhiannon J Walters; Kevin J Spring; Belinda Nagler; Erika Pavluk; Sven T Arnold; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry Phillips; John L Hopper; Jeremy R Jass; John A Baron; Dennis J Ahnen; Stephen N Thibodeau; Noralane Lindor; Susan Parry; Neal I Walker; Christophe Rosty; Joanne P Young
Journal:  Mod Pathol       Date:  2012-02-10       Impact factor: 7.842

Review 6.  Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.

Authors:  Henry T Lynch; Kristen Drescher; Joseph Knezetic; Stephen Lanspa
Journal:  Curr Treat Options Oncol       Date:  2014-09

7.  Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours.

Authors:  A Pagin; F Zerimech; J Leclerc; A Wacrenier; S Lejeune; C Descarpentries; F Escande; N Porchet; M-P Buisine
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

Review 8.  Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Authors:  Angela Toss; Chiara Tomasello; Elisabetta Razzaboni; Giannina Contu; Giovanni Grandi; Angelo Cagnacci; Russell J Schilder; Laura Cortesi
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

Review 9.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

10.  Improved Detection of Microsatellite Instability in Early Colorectal Lesions.

Authors:  Jeffery W Bacher; Chelsie K Sievers; Dawn M Albrecht; Ian C Grimes; Jennifer M Weiss; Kristina A Matkowskyj; Rashmi M Agni; Irina Vyazunova; Linda Clipson; Douglas R Storts; Andrew T Thliveris; Richard B Halberg
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.